^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/19/2015
    Excerpt:
    OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of...patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel recommends nivolumab as a category 2A option for select patients with advanced RCC with non-clear cell histology…
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Int J Clin Oncol
    Title:

    A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

    Published date:
    06/09/2020
    Excerpt:
    Median progression-free survival was 7.1 months, the objective response rate was 22.6%, and median duration of response was 13.3 months….Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients.
    DOI:
    https://doi.org/10.1007/s10147-020-01692-z